¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀåÀº 2023³â¿¡´Â 39¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2031³â¿¡´Â 59¾ï 3,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024³âºÎÅÍ 2031³â±îÁö º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 5.2%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
º¸°í ¹üÀ§ |
º¸°í¼ ¼¼ºÎÁ¤º¸ |
±âÁسâ |
2023 |
2023/2024³â ½ÃÀå ±Ô¸ð |
39¾ï 6,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2019³â-2023³â |
¿¹Ãø ±â°£ |
2024-2031 |
¿¹Ãø ±â°£ 2023/2024-2030/2031 º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR): |
5.20% |
2030/2031³â ¿¹ÃøÄ¡ |
59¾ï 3,000¸¸ ´Þ·¯ |
±×¸² 1. º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀå Á¡À¯À²(%), Áö¿ªº°(2023³â)
º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA)´Â ¿©·¯ ¼Ò½º ¹× ¾ç½Ä¿¡¼ ¸ðµç ÀÇ·á ¿ëµµ¿¡¼ ÀÇ·á À̹ÌÁö ¹× °ü·Ã º¸°í¼¸¦ ÀúÀå, Á¶È¸ ¹× °Ë»öÇÒ ¼ö ÀÖ´Â À̹ÌÁö °ü¸® ¼Ö·ç¼ÇÀÔ´Ï´Ù. ÀüÅëÀûÀ¸·Î °Ç° °ü¸® Á¶Á÷Àº ¹æ»ç¼± À̹ÌÁö¸¦ ÀúÀåÇÏ°í ¾×¼¼½ºÇϱâ À§ÇØ ¿©·¯ PACS ½Ã½ºÅÛÀ» °ü¸®ÇØ¾ß ÇßÀ¸¸ç ºñ¿ë°ú ±â¼úÀû º¹À⼺À» Áõ°¡ ½ÃÄ×½À´Ï´Ù. VNA´Â ¸ðµç Áø·á°ú, Ãâó ¹× Àü¹® ºÐ¾ßÀÇ À̹ÌÁö µ¥ÀÌÅ͸¦ ´ÜÀÏ ¾ÆÄ«À̺꿡 ÅëÇÕÇÏ´Â Áß¾Ó ÀúÀå¼Ò¸¦ Á¦°øÇÕ´Ï´Ù. À̸¦ ÅëÇØ »óÈ£ ¿î¿ë¼º, ¹ü¿ë ¾×¼¼½º ¹× ÃÖÀûÈµÈ ÀÇ·á Çù·ÂÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ:
º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼º ÁúȯÀÇ ¸¸¿¬¿¡ ÀÇÇÑ È»ó 󸮷® Áõ°¡, ÀÇ·á¿ë È»óÀÇ ÁýÁß º¸°ü ½Ã½ºÅÛ¿¡ ´ëÇÑ ±âÈ£ÀÇ Çâ»ó, ´Ù¾çÇÑ ÀÇ·á Á¦°ø ȯ°æ¿¡¼ÀÇ µ¥ÀÌÅÍ °øÀ¯ÀÇ °³¼±°ú ȯÀÚ ÄɾîÀÇ Á¦ÈÞ °È ÇÊ¿ä µîÀÇ ¿äÀο¡ ÀÇÇØ Á¦°øµË´Ï´Ù. ±×·¯³ª VNAÀÇ µµÀÔ°ú À¯Áöº¸¼ö¿¡ µå´Â ºñ¿ëÀÌ ³ô°í, ƯÈ÷ ¼Ò±Ô¸ð ÀÇ·á½Ã¼³¿¡¼´Â Àü¹® Áö½ÄÀÌ ºÎÁ·Çϱ⠶§¹®¿¡ º¸±Þ¿¡´Â ÇÑ°è°¡ ÀÖ½À´Ï´Ù. ÇÑÆí, ¿ø°ÝÀÇ·á½ÇõÀÇ È®´ë, ÀΰøÁö´ÉÀÇ ÅëÇÕÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼úÀÇ Áøº¸, ¿¹Ãø ºÐ¼®Àº º¥´õ¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Ư¡
- ÀÌ Á¶»ç º¸°í¼´Â ¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ°í, 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø ±â°£(2024³â-2031³â) ½ÃÀå ±Ô¸ð ¹× º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)%À» °ÔÀçÇß½À´Ï´Ù.
- ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ¼ºÀå ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾ÈÀÇ Çà·Ä¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.
- ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä °íÂûµµ Á¦°øÇÕ´Ï´Ù.
- ÀÌ º¸°í¼´Â Àü ¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ¼º°ú, À繫 ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
- ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®À» ÅëÇØ ¸¶ÄÉÆà ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆà Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
- ¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
- ÀÌÇØ°ü°èÀÚ´Â ¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç °áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
- º¸°í¼ ¼³¸í
- ÁÖ¿ä ¿ä¾à
- Coherent Opportunity Map(COM)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¿µÇ⠺м®
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ±ÔÁ¦ ½Ã³ª¸®¿À
- ¼ºñ½º Á¦°ø Æ÷Æ®Æú¸®¿À
- PEST ºÐ¼®
- Porter's Five Forces ºÐ¼®
- ÇÕº´°ú Àμö ½Ã³ª¸®¿À
- ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
Á¦4Àå ¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀå-Äڷγª ¹ÙÀÌ·¯½º(COVID-19) À¯ÇàÀÇ ¿µÇâ
- ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿ªÇÐ
- °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
- °æÁ¦Àû ¿µÇâ
Á¦5Àå ¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀå : Àü°³ ¸ðµ¨º°(2019³â-2031³â)
- ¿ÂÇÁ·¹¹Ì½º VNA
- Ŭ¶ó¿ìµå ±â¹Ý VNA
Á¦6Àå ¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀå : º¥´õ À¯Çüº°(2019³â-2031³â)
- µ¶¸³ ¼ÒÇÁÆ®¿þ¾î º¥´õ(ISV)
- PACS º¥´õ
- ÀÎÇÁ¶óº¥´õ
Á¦7Àå ¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀå : À̹Ì¡ À¯Çüº°(2019³â-2031³â)
- ¹æ»ç¼±°ú VNA
- ½ÉÀ庴ÇÐ VNA
- º´¸®ÇÐ VNA
Á¦8Àå ¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2019³â-2031³â)
- º´¿ø
- È»ó Áø´Ü¼¾ÅÍ
- ¿Ü·¡ Áø·á ¼¾ÅÍ
- ¿¬±¸±â°ü ¹× Çмú±â°ü
Á¦9Àå ¼¼°è º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀå : Áö¿ªº°(2019³â-2031³â)
- ºÏ¹Ì
- À¯·´
- µ¶ÀÏ
- ¿µ±¹
- ½ºÆäÀÎ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ASEAN
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¾Æ¸£ÇîƼ³ª
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- 秵- GCC ±¹°¡
- À̽º¶ó¿¤
- ±âŸ Áßµ¿
- ¾ÆÇÁ¸®Ä«
- ºÏ¾ÆÇÁ¸®Ä«
- Áß¾Ó ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
Á¦10Àå °æÀï ±¸µµ
- Johnson & Johnson Private Limited
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Baxter
- Bayer AG
- Eli Lilly and Company
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Lupin
- Allergan
- AbbVie Inc.
- Abbott
- Bausch Health Companies Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Mylan NV
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- AstraZeneca
Á¦11Àå ¼½¼Ç
BJH 24.04.25
The global vendor neutral archive (VNA) market was valued US$ 3.96 Bn in 2023 and is expected to reach US$ 5.93 Bn by 2031 growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
Report Coverage |
Report Details |
Base Year: |
2023 |
Market Size in 2023/2024: |
US$ 3.96 Bn |
Historical Data for: |
2019 to 2023 |
Forecast Period: |
2024 - 2031 |
Forecast Period 2023/2024 to 2030/2031 CAGR: |
5.20% |
2030/2031 Value Projection: |
US$ 5.93 Bn |
Figure 1. Global Vendor Neutral Archive (VNA) Market Share (%), By Region, 2023
Vendor neutral archive (VNA) is an image management solution that allows medical images and associated reports to be stored, queried, and retrieved by any healthcare application from multiple sources and modalities. Traditionally, healthcare organizations have had to manage multiple PACS systems to store and access radiology images which led to increased costs and technological complexities. A VNA provides a central repository that consolidates imaging data from all departments, sources, and specialties in a single archive. This facilitates interoperability, universal access, and optimized care collaboration.
Market Dynamics:
The growth of the vendor neutral archive (VNA) market is driven by factors such as rising imaging volumes due to increasing prevalence of chronic diseases, growing preferences for centralized medical imaging storage systems, and need to improve data sharing and enhance patient care coordination across various care delivery settings. However, high costs associated with the deployment and maintenance of VNAs as well as lack of expertise especially in small healthcare facilities limit their widespread adoption. Meanwhile, growing telehealth practices, technological advancements to enable artificial intelligence integration, and predictive analytics present lucrative opportunities for vendors.
Key features of the study:
- This report provides an in-depth analysis of the global vendor neutral archive (VNA) market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2022 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global vendor neutral archive (VNA) market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Johnson & Johnson Private Limited, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Baxter, Bayer AG, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin , Allergan, AbbVie Inc., Abbott, Bausch Health Companies Inc. , Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, and AstraZeneca
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global vendor neutral archive (VNA) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vendor neutral archive (VNA) market
Detailed Segmentation:
- Global Vendor Neutral Archive (VNA) Market, By Deployment Model
- On-Premise VNA
- Cloud-Based VNA
- Global Vendor Neutral Archive (VNA) Market, By Vendor Type
- Independent Software Vendors (ISVs)
- PACS Vendors
- Infrastructure Vendors
- Global Vendor Neutral Archive (VNA) Market, By Imaging Type
- Radiology VNAs
- Cardiology VNAs
- Pathology VNAs
- Global Vendor Neutral Archive (VNA) Market, By End-User
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Care Centers
- Research and Academic Institutes
- Global Vendor Neutral Archive (VNA) Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Global Vendor Neutral Archive (VNA) Market, Key Players
- Johnson & Johnson Private Limited
- Merck & Co., Inc.
- F.Hoffmann-La Roche Ltd.
- Baxter
- Bayer AG
- Eli Lilly and Company
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Lupin
- Allergan
- AbbVie Inc.
- Abbott
- Bausch Health Companies Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- AstraZeneca
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Vendor Neutral Archive (VNA) Market, By Deployment Model
- Global Vendor Neutral Archive (VNA) Market, By Vendor Type
- Global Vendor Neutral Archive (VNA) Market, By Imaging Type
- Global Vendor Neutral Archive (VNA) Market, By End User
- Global Vendor Neutral Archive (VNA) Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing adoption of cloud-based VNA solutions
- Growing adoption of imaging equipment across healthcare facilities
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Service Offering Portfolio
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Pipeline Analysis
4. Global Vendor Neutral Archive (VNA) Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Vendor Neutral Archive (VNA) Market, By Deployment Model, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- On-premise VNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
- Cloud-based VNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
6. Global Vendor Neutral Archive (VNA) Market, By Vendor Type, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Independent Software Vendors (ISVs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
- PACS Vendors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
- Infrastructure Vendors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
7. Global Vendor Neutral Archive (VNA) Market, By Imaging Type, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Radiology VNAs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
- Cardiology VNAs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
- Pathology VNAs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
8. Global Vendor Neutral Archive (VNA) Market, By End User, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
- Diagnostic Imaging Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
- Ambulatory Care Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
- Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
9. Global Vendor Neutral Archive (VNA) Market, By Region, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019 - 2031
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Deployment Model, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Vendor Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Imaging Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Deployment Model, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Vendor Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Imaging Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Deployment Model, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Vendor Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Imaging Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Deployment Model, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Vendor Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Imaging Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Deployment Model, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Vendor Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Imaging Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Deployment Model, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Vendor Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Imaging Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2019-2031,(US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Johnson & Johnson Private Limited
- Company Highlights
- Deployment Model Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Deployment Model Portfolio
- Key Highlights
- Financial Performance
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Deployment Model Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Baxter
- Company Highlights
- Deployment Model Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bayer AG
- Eli Lilly and Company
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Lupin
- Allergan
- AbbVie Inc.
- Abbott
- Bausch Health Companies Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- AstraZeneca
- Analyst Views
11. Section
- Research Methodology
- About us